Cryoport (CYRX) Misses Q4 EPS by 13c

Go back to Cryoport (CYRX) Misses Q4 EPS by 13c

Cryoport Reports Fourth Quarter and Full Year 2024 Financial Results

March 4, 2025 4:11 PM EST

FY 2024 revenue of $228.4 million, in-line with company guidanceCommercial Cell & Gene Therapy revenue rose to $26 million in FY 2024, up 20% year-over-year Supporting a record total of 701 global clinical trials as of December 31, 2024

NASHVILLE, Tenn., March 4, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:... More